医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Taro to Announce Results for Year Ended March 31, 2015 on May 26, 2015

2015年05月20日 AM04:55
このエントリーをはてなブックマークに追加


 

HAWTHORNE, N.Y.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2015, on Tuesday, May 26, 2015.

The Company will conduct an earnings call at 8:00 am ET on Thursday, May 28, 2015, where senior management will discuss the Company’s performance and answer questions from participants.

The release will be accessible on Taro’s website at www.taro.com.

Earnings Call (8:00 am ET on Thursday, May 28, 2015)

To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.taro.com. A transcript of this earnings call will also be available on the website.

Summary of events

       
Event   Date and time   Telephone number/ website
Earnings release   May 26, 2015  

www.taro.com

Earnings conference call  

8:00 am ET

May 28, 2015

 

Participant Toll-Free Dial-In Number: +1 (844) 421-0601

Participant International Dial-In Number: +1 (716) 247-5800

ID: 49865423

 

Via audio webcast, details of which will be made available on www.taro.com

Replay of conference call   May 28, 2015 to

June 12, 2015

 

+ 1 (855) 859-2056 or +1 (404) 537-3406

ID: 49865423

 

Via audio webcast playback, details of which will be made available on www.taro.com

   

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150519007083/en/

CONTACT

Taro Pharmaceutical Industries Ltd.
Michael Kalb, 914-345-9001
GVP,
CFO
Michael.Kalb@taro.com
or
William
J. Coote, 914-345-9001
William.Coote@taro.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表